Dr. David Steensma specializes in care and research for myelodysplastic syndromes and leukemia. He and colleagues were the first to identify and understand the clinical implications of the clonal hematopoiesis of indeterminate potential (CHIP). He is an Associate Editor of the Journal of Clinical Oncology responsible for the “Art of Oncology” section and has more than 150 publications in peer-reviewed journals. Dr. Steensma currently serves as an Associate Professor of Medicine at Harvard Medical School, consulting physician at Brigham & Women’s Hospital, and a faculty member in the Adult Leukemia Program at Dana-Farber Cancer Institute in Boston.
